Should We Treat Children with Idiopathic Short Stature?
Workshop Held in St.-Paul-de-Vence, France, April 18–19, 1999Kelnar C.J.H.a · Albertsson-Wikland K.b · Hintz R.L.c · Ranke M.B.d · Rosenfeld R.G.e
aDepartment of Child Life and Health, University of Edinburgh, Edinburgh, UK; bGöteborg Pediatric Growth Research Centre, University of Göteborg, Göteborg, Sweden; cDepartment of Pediatrics, Division of Endocrinology, Stanford University Medical Center, Stanford, Calif., USA; dPediatric Endocrinology Section, Eberhard-Karls-Universität, Tübingen, Germany, and eDivision of Pediatric Endocrinology, Oregon Health Sciences University, Portland, Oreg., USA
The use of growth hormone (GH) to treat short children who are clearly GH-deficient is now well accepted. However, GH treatment of short children who have no currently recognizable abnormalities in their GH-insulin-like growth factor I axis remains controversial. Whether such children with so-called idiopathic short stature (ISS) should be treated with GH was the subject of an international workshop held in St.-Paul-de-Vence, France, in April 1999. This article summarizes the issues discussed at the workshop, including the definition of ISS, ethical and health-economic aspects of treatment, results from clinical trials and surveillance studies, and the use of prediction models in aiding treatment decisions.
© 2000 S. Karger AG, Basel
Received: Received: November 8, 1999
Accepted: November 12, 1999
Number of Print Pages : 8
Number of Figures : 0, Number of Tables : 1, Number of References : 29
Hormone Research (International Journal of Experimental and Clinical Endocrinology)
Founded 1970 as ‘Hormones’ by M. Marois, Continued 1976 by J. Girard (1976–1995)
Official Organ of the European Society for Paediatric Endocrinology
Vol. 52, No. 3, Year 1999 (Cover Date: September 1999 (Released February 2000))
Journal Editor: M.B. Ranke, Tübingen
ISSN: 0301–0163 (print), 1423–0046 (Online)
For additional information: http://www.karger.com/journals/hre